L1CAM and endometrioid adenocarcinoma: L1CAM (clone 14.10, dilution 1:200, cutoff 10%) was studied in 626 stage I endometrioid carcinoma patients, finding expression in 8% of them and no association with survival in the multivariate analysis, but its expression in the non-specific molecular subgroup was associated with poor outcome [66].